ArticleFrontiers in neurology2026
Early high-dose intravenous methylprednisolone is associated with faster symptom improvement in persistent ocular myasthenia gravis: a single-center retrospective study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-dose intravenous methylprednisolone pulse therapy (HMP) may provide rapid symptom relief in ocular myasthenia gravis (MG), but the clinical impact of its early use as induction immunotherapy remains unclear. We evaluated whether early HMP was associated with more rapid symptom improvement in patients with persistent ocular MG. Methods: This single-center retrospective study included 36 patients with ocular MG who received corticosteroid-based immunotherapy and remained classified as having ocular MG throughout 2 years of follow-up. Patients were categorized according to their initial immunotherapy strategy into an early HMP induction group ( Results: Baseline ocular MG-ADL scores were higher in the HMP group (mean ± standard deviation, 4.842 ± 1.642 vs. 3.353 ± 1.057). The mixed-effects model demonstrated a significant group-by-time interaction ( Conclusion: In persistent ocular MG, early HMP as part of induction immunotherapy was associated with faster ocular symptom improvement and earlier achievement of minimal symptom expression than OCS induction alone, while long-term clinical outcomes and oral prednisolone doses were similar. Early HMP may be useful when rapid symptom control is required, although prospective studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.